Caribou Biosciences, Inc. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Caribou Biosciences announced it is evaluating strategic alternatives (merger, acquisition, or asset sale) and discontinuing development of vispa-cel and CB-011 allogeneic CAR-T therapies due to financing challenges in the CAR-T market. The company will implement substantial workforce reductions expected to complete in Q4 2026. As of June 30, 2026, Caribou held $113.8 million in cash, cash equivalents, and marketable securities—essentially equal to the company's ~$112.5M public market value.
Why this rating
Company abandoning all lead pipeline programs and pursuing sale/merger; cash position (~100% of market cap) means near-total dilution likely; existential pivot for clinical-stage biotech.
Tradability signal
SHORT
conviction 67/100 · expected -2.99% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (63 in this cell) moved +4.18% in the called direction over 4 hrs; shrunk for sample size that's a +2.99% edge. Price is down 47.5% since the filing hit EDGAR — the slide has begun. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $1.14 ▲ 80.73% | at our read · unknown $0.63 | +10 min · unknown $0.59 ▼ 5.73% | +30 min · unknown $0.58 ▼ 7.48% | +1 hr · unknown $0.64 ▲ 1.11% | +4 hrs · unknown $0.61 ▼ 2.39% |
The stock had already moved -44.67% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.